Drug
Rubitecan clinical trials
- studies test it
- 16
- open now
- 0
- in phase 3
- 1
- first study started
- 1999
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2000 (7)
| Year | Studies |
|---|---|
| 1999 | 5 |
| 2000 | 7 |
| 2001 | 1 |
| 2003 | 1 |
| 2005 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 14
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
Astex Pharmaceuticals, Inc. (8) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Alliance for Clinical Trials in Oncology (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · University of New Mexico (1) · Gynecologic Oncology Group (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rubitecan is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study of Rubitecan in Cancer Patients With Renal or Hepatic DysfunctionCompletedPhase 1Astex Pharmaceuticals, Inc.NCT00113113Written as Rubitecan
- Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic CancerTerminatedPhase 2/3Astex Pharmaceuticals, Inc.NCT00113256Written as Rubitecan
- Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone TherapyCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00005820Written as nitrocamptothecin
- Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedPhase 2Astex Pharmaceuticals, Inc.NCT00005873Written as rubitecan
- Nitrocamptothecin in Treating Patients With Soft Tissue SarcomasCompletedPhase 2Astex Pharmaceuticals, Inc.NCT00005874Written as rubitecan
- Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung CancerCompletedPhase 2Astex Pharmaceuticals, Inc.NCT00005872Written as rubitecan
- Nitrocamptothecin in Treating Patients With Metastatic MelanomaCompletedPhase 2Astex Pharmaceuticals, Inc.NCT00005875Written as rubitecan
- Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During SurgeryStatus unknownPhase 2Astex Pharmaceuticals, Inc.NCT00005876Written as rubitecan
- Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal CancerStatus unknownPhase 2Astex Pharmaceuticals, Inc.NCT00005877Written as rubitecan
- Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal CancerWithdrawnPhase 2Gynecologic Oncology GroupNCT00006267Written as rubitecan
- Combination Therapy With Oral 9-Nitrocamptothecin & Oral EtoposideCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT00006047Written as Oral 9-Nitrocamptothecin
- Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung CancerCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00006082Written as rubitecan
- Nitrocamptothecin in Treating Patients With Advanced Ovarian CancerCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00006230Written as rubitecan
- Nitrocamptothecin in Treating Patients With Glioblastoma MultiformeCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00005826Written as rubitecan
- Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary TractCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00006026Written as rubitecan
- Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)CompletedPhase 2University of New MexicoNCT00250068Written as Liposomal 9-Nitrocamptothecin
Codes
What other systems call rubitecan · ClinicalTrials.gg INT003711
- MeSH (NLM) C079905rubitecanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) H19C446XXBRUBITECANConfirmed FDA, NLM, Wikidata
- Wikidata Q510113rubitecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1485RubitecanOne source FDA
- DrugBank DB06159One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C079905 | rubitecan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | H19C446XXB | RUBITECAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q510113 | rubitecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1485 | Rubitecan | One source FDA |
| DrugBank | DB06159 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.